Zynex stock (US98986M1036): earnings update keeps medtech growth story in focus

Zynex has reported weaker first-quarter 2025 results and cut its full-year outlook, while the stock remains volatile on Nasdaq. What is driving the story behind this US pain-management device specialist?

Zynex reported mixed first-quarter 2025 results with lower revenue and earnings compared with the prior-year period and trimmed its full-year 2025 guidance, according to a results release dated 04/29/2025 on the company’s investor relations site and coverage by Nasdaq as of 04/29/2025. Shortly after the announcement, the stock traded noticeably below its 52?week highs on Nasdaq, reflecting investor caution after the new outlook, according to price data on MarketWatch as of 04/30/2025.

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Zynex Inc
• Sector/industry: Medical devices / pain management
• Headquarters/country: Englewood, Colorado, United States
• Core markets: Outpatient pain management and neurology clinics in the US
• Key revenue drivers: Electrotherapy devices and recurring supply sales
• Home exchange/listing venue: Nasdaq Capital Market (ticker: ZYXI)
• Trading currency: US dollar (USD)

Zynex: core business model

Zynex develops and markets non-invasive medical devices that are primarily used for pain management and rehabilitation. Its core products include electrotherapy systems designed to deliver electrical stimulation to nerves and muscles, which doctors prescribe as alternatives or complements to pharmaceutical pain treatments, according to the company’s business description in its annual report for 2023 published on 03/14/2024 on the investor relations site Zynex investor information as of 03/14/2024. The company’s business model combines the sale or rental of devices with recurring revenue from electrodes and other disposables required for continued therapy.

The firm’s main electrotherapy platform, which includes devices such as the NexWave multi?modal stimulation unit, is targeted at patients suffering from chronic or post?surgical pain. Physicians typically prescribe the devices, while Zynex manages insurance billing and logistics, creating a service layer around the hardware, according to product information on the corporate website and commentary in the 2023 Form 10?K filed on 03/14/2024 with the US Securities and Exchange Commission SEC filing as of 03/14/2024. This combination of devices and supplies aims to build a recurring relationship with prescribing clinics and their patients.

Besides its flagship pain therapy line, Zynex has been developing additional monitoring and diagnostic technologies to diversify its portfolio, including non?invasive monitoring systems for blood loss and fluid levels. While these newer products contribute less revenue today, management has emphasized them as potential growth drivers for the medium term in its 2023 annual report and conference call commentary from 03/14/2024, according to Seeking Alpha as of 03/14/2024. The strategic goal is to broaden the addressable market beyond pain management clinics into hospital and acute care settings.

The company operates largely within the US healthcare reimbursement environment, which means that it depends on approvals and payments from private insurers, Medicare and other payors. Zynex handles much of the reimbursement process directly, rather than relying on third?party distributors, which requires operational scale but allows the firm to retain more margin per therapy, according to explanations in the 2023 Form 10?K filed on 03/14/2024 SEC filing as of 03/14/2024. This integrated approach is a central part of the business model and distinguishes Zynex from some device peers that sell primarily through distributors.

Main revenue and product drivers for Zynex

Zynex generates most of its revenue from its electrotherapy pain management products and associated supplies, particularly through the NexWave device and electrode kits. Recurring orders for consumables often follow an initial device prescription, and management has repeatedly highlighted that this consumable stream can last for months or even years per patient, according to the 2023 annual report published 03/14/2024 and Q4 2023 earnings commentary summarized by Motley Fool as of 03/14/2024. This recurring component tends to stabilize revenue compared with a pure capital equipment model, although order volumes can still fluctuate with physician prescribing trends.

To fuel growth, Zynex has been expanding its nationwide salesforce of medical device representatives who target pain clinics, orthopedics and physical therapy practices. Over the past several years, the company has increased the number of field representatives, and management again referenced its salesforce expansion as a key driver in the Q4 2023 call on 03/14/2024, according to Seeking Alpha as of 03/14/2024. The strategy aims to increase physician awareness and deepen relationships with existing prescribers, which can translate into higher prescription volumes and sustained supply orders over time.

Another potential revenue driver is Zynex’s push into patient monitoring devices meant for hospital and surgical settings, such as its non?invasive monitoring products designed to track blood loss or fluid changes. These products remain in earlier stages of commercialization and contribute a smaller portion of total sales, but they address different clinical environments and reimbursement pathways than the core pain therapy line. Management highlighted ongoing investments and research efforts around these monitoring technologies in its 2023 Form 10?K filed on 03/14/2024, stating that the goal is to build a broader portfolio that can appeal to both outpatient and inpatient providers, according to the SEC filing as of 03/14/2024.

From a profitability perspective, Zynex’s gross margins have historically been relatively high for a device company, supported by the recurring nature of supplies and in?house billing capabilities. In its 2023 annual report published 03/14/2024, the company reported gross margin above 75% for 2023, driven by a favorable product mix and operational efficiencies, according to the Zynex annual report as of 03/14/2024. However, operating margin has been more volatile as Zynex invests in salesforce expansion, research and development, and infrastructure upgrades, which can temporarily raise expenses relative to revenue growth.

In the Q1 2025 earnings announcement dated 04/29/2025, Zynex reported lower net income compared with the same quarter of the previous year, largely reflecting higher selling, general and administrative expenses associated with growth initiatives and cost pressures, according to Nasdaq as of 04/29/2025. The company also revised its full?year 2025 revenue and earnings guidance downward, citing a slower?than?expected ramp?up in some sales territories and ongoing reimbursement hurdles in certain states, based on statements in the earnings release the same day on the investor relations website Zynex investor information as of 04/29/2025. These updates underscored how sensitive near?term results can be to operational execution and payor dynamics.

Despite the near?term guidance cut, management reiterated its belief in the long?term growth potential of non?invasive pain therapies and monitoring devices. The company noted that demand for opioid?sparing pain options remains an important theme among clinicians and policymakers, which could support increased utilization of electrotherapy solutions over time, according to commentary from the Q1 2025 conference call on 04/29/2025 summarized by Seeking Alpha as of 04/29/2025. For Zynex, the challenge will be to capture this demand while managing reimbursement complexities and sustaining profitability as it scales.

Industry trends and competitive position

Zynex operates within the broader medical device industry, with a focus on pain management technologies that offer alternatives to or support for pharmaceutical treatments. Over the last decade, the opioid crisis in the United States has driven regulators, payors and clinicians to explore non?opioid options for chronic and post?surgical pain, creating a more favorable environment for therapies such as electrostimulation and physical rehabilitation, according to policy analyses and healthcare commentary compiled by the US Centers for Disease Control and Prevention and summarized by CDC information as of 11/03/2023. This macro trend represents a structural driver for companies like Zynex that specialize in non?pharmacologic interventions.

In the electrotherapy and neuromodulation space, Zynex competes with both specialized device makers and larger diversified medtech companies. Some rivals focus on implantable spinal cord stimulators, while others provide external devices for transcutaneous electrical nerve stimulation. Larger players may have broader product lines and more extensive hospital relationships, but smaller specialists can sometimes respond more quickly to niche clinical needs or shifts in reimbursement, according to a market overview by Medical Product Outsourcing as of 01/10/2024. Zynex’s strategy of directly serving outpatient clinics and handling reimbursement in?house sets it apart in this fragmented competitive landscape.

Regulatory and reimbursement frameworks are critical for the industry and can influence both adoption rates and pricing power. Medical devices for pain management must meet safety and efficacy standards set by agencies such as the US Food and Drug Administration, and coverage decisions by Medicare Administrative Contractors or private insurers can significantly affect utilization. Changes in coding, coverage policies or documentation requirements may impact how easily physicians can prescribe therapies and get reimbursed. Zynex highlighted reimbursement risk as a key uncertainty in its 2023 Form 10?K filed on 03/14/2024, noting that payor audits, policy changes or delays in claims processing can influence cash flow and revenue timing, according to the SEC filing as of 03/14/2024. This environment requires close monitoring by investors following medtech stocks.

Why Zynex matters for US investors

For US investors, Zynex represents a small to mid?cap medical device company positioned at the intersection of pain management, rehabilitation and non?opioid therapeutics. The stock trades on the Nasdaq Capital Market under the ticker ZYXI, which provides accessibility and liquidity for US retail investors and facilitates inclusion in certain healthcare or small?cap indices, according to listing information on Nasdaq as of 04/30/2025. Because Zynex’s revenue is heavily concentrated in the United States, its performance is closely tied to US healthcare spending trends, insurance coverage policies and macroeconomic conditions influencing elective procedures.

Medtech stocks like Zynex can behave differently from broader market indices in certain environments, particularly when product cycles or regulatory milestones drive company?specific catalysts. For example, updates on clinical studies, new product launches or regulatory clearances can influence investor sentiment independent of general economic data. At the same time, smaller healthcare companies may exhibit higher volatility and sensitivity to quarterly earnings surprises or guidance revisions, as was visible after Zynex’s Q1 2025 earnings release and outlook cut on 04/29/2025, described by Nasdaq as of 04/29/2025. This pattern can be relevant for investors assessing the risk–return profile of niche medical technology names.

Furthermore, Zynex’s business may be viewed in the context of longer?term healthcare themes such as aging populations, chronic pain prevalence and the shift toward outpatient care. Devices that enable at?home or clinic?based therapies could benefit from healthcare systems’ efforts to reduce hospital stays and manage chronic conditions more efficiently. For US investors interested in thematic exposure to non?opioid pain solutions and outpatient rehabilitation, Zynex offers a focused play within a specific device niche, though its scale and concentration also mean that company?specific execution risk remains important, as underlined by the company’s cautious full?year 2025 guidance announced on 04/29/2025 on the investor relations site Zynex investor information as of 04/29/2025.

Conclusion

Zynex stands out as a focused US medical device company centered on non?invasive pain management and emerging monitoring technologies. The business model relies on the combination of electrotherapy hardware, recurring consumable sales and in?house reimbursement capabilities, which together have supported attractive gross margins in recent years, according to the 2023 annual report published 03/14/2024 on the investor relations site Zynex annual report as of 03/14/2024. At the same time, the company’s Q1 2025 results and downward?revised outlook, announced on 04/29/2025, highlight that growth is not linear and that expenses, salesforce productivity and reimbursement conditions can all weigh on near?term profitability, as reported by Nasdaq as of 04/29/2025. For investors, the stock’s appeal will likely depend on views around Zynex’s execution in expanding its sales footprint, navigating insurer requirements and bringing new monitoring products to market, alongside broader considerations such as tolerance for earnings volatility and the desire for exposure to non?opioid pain management themes in the US healthcare system.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.